Tumor Lysis Syndrome

"Tumor Lysis Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.

Descriptor ID	D015275
MeSH Number(s)	C15.604.515.880 C20.683.515.950
Concept/Terms	Tumor Lysis Syndrome Tumor Lysis Syndrome Syndrome, Tumor Lysis Syndromes, Tumor Lysis Tumor Lysis Syndromes Tumour Lysis Syndrome Syndrome, Tumour Lysis Syndromes, Tumour Lysis Tumour Lysis Syndromes

Below are MeSH descriptors whose meaning is more general than "Tumor Lysis Syndrome".

Diseases [C]
Hemic and Lymphatic Diseases [C15]
Lymphatic Diseases [C15.604]
Lymphoproliferative Disorders [C15.604.515]
Tumor Lysis Syndrome [C15.604.515.880]
Immune System Diseases [C20]
Immunoproliferative Disorders [C20.683]
Lymphoproliferative Disorders [C20.683.515]
Tumor Lysis Syndrome [C20.683.515.950]

Below are MeSH descriptors whose meaning is more specific than "Tumor Lysis Syndrome".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Tumor Lysis Syndrome" by people in this website by year, and whether "Tumor Lysis Syndrome" was a major or minor topic of these publications.

Bar chart showing 7 publications over 7 distinct years, with a maximum of 1 publications in 2005 and 2008 and 2009 and 2011 and 2013 and 2016 and 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	1	0	1
2008	0	1	1
2009	0	1	1
2011	1	0	1
2013	1	0	1
2016	1	0	1
2022	1	0	1

Below are the most recent publications written about "Tumor Lysis Syndrome" by people in Profiles.

Kube P, Parisio K, Mangum DS, Powell J. Fusion-negative rhabdomyosarcoma with diffuse bony metastases and remarkable chemosensitivity. BMJ Case Rep. 2022 Aug 29; 15(8).

View in: PubMed
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016 06; 6(6):664-79.

View in: PubMed
Kutsch E, Kreiger P, Consolini D, Furuya KN. Colonic perforation after rituximab treatment for posttransplant lymphoproliferative disorder. J Pediatr Gastroenterol Nutr. 2013 Jun; 56(6):e41.

View in: PubMed
Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5.

View in: PubMed
Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bola?os-Meade J, Greer JM, Carraway HE, Gore SD, Jones RJ, Levis MJ, McDevitt MA, Doyle LA, Wright JJ. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res. 2010 Jul; 34(7):877-82.

View in: PubMed
Feusner JH, Ritchey AK, Cohn SL, Billett AL. Management of tumor lysis syndrome: need for evidence-based guidelines. J Clin Oncol. 2008 Dec 01; 26(34):5657-8; author reply 5658-9.

View in: PubMed
Lehner SG, Gould JE, Saad WE, Brown DB. Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma. AJR Am J Roentgenol. 2005 Nov; 185(5):1307-9.

View in: PubMed
Sakarcan A, Quigley R. Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol. 1994 Jun; 8(3):351-3.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement